Expertise in
33
conditions

Anna Szymanska-Tylki

Warsaw, MZ, PL 
Expertise in
33
conditions
Warsaw, MZ, PL 

Overview

Anna Szymanska-Tylki practices practicing medicine in Warsaw, Poland.

Ms. Szymanska-Tylki is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), Gaucher Disease, Mucopolysaccharidosis Type 6 (MPS VI, Maroteaux-Lamy Syndrome), Liver Transplant, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 179 peer reviewed articles and participating in 6 clinical trials.

Gender

Female

Locations

Warsaw, MZ 04730, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Arimoclomol
Study Phase: Phase 2/Phase 3
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug
Biomarker for Niemann Pick Type C Disease (NPC1/NPC2) an International, Multicenter, Epidemiological Study
Biomarker for Niemann Pick Type C Disease (NPC1/NPC2) an International, Multicenter, Epidemiological Study
Enrollment Status: Withdrawn
Publish Date: February 13, 2023
Biomarkers for Hunter Syndrome: An International, Multicenter, Observational, Longitudinal Protocol
Biomarkers for Hunter Syndrome: An International, Multicenter, Observational, Longitudinal Protocol
Enrollment Status: Terminated
Publish Date: February 10, 2023
A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy
A Multi-Center, Open-Label Study Evaluating Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Enzyme Replacement Therapy
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Biological
Study Phase: Phase 4
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern
A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern
Enrollment Status: Completed
Publish Date: May 18, 2017
View 5 Less Clinical Trials

179 Total Publications

Safety and Efficacy of Ambroxol Therapy in Polish Patients with Gaucher Disease.
Safety and Efficacy of Ambroxol Therapy in Polish Patients with Gaucher Disease.
Journal: Life (Basel, Switzerland)
Published: January 09, 2026

Frequently Asked Questions about Anna Szymanska-Tylki

Is Anna Szymanska-Tylki a top-rated expert for Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)?

MediFind is an objective health platform that identifies experts based on real-world data. Anna Szymanska-Tylki is classified as an Elite expert for Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Anna Szymanska-Tylki participate in research or clinical trials?

Yes. Anna Szymanska-Tylki has published 179 articles and abstracts on conditions like Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome). You can view a list of Anna Szymanska-Tylki's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Szymanska-Tylki's expertise for a condition
ConditionClose
View All 16 Distinguished Conditions
View All 14 Advanced Conditions
View All 42 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile